DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for urinary bladder cancer — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleUrinary bladder cancer maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for urinary bladder cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ras homolog family member A (RHOA) — RHOA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5C4M · 1.3 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Bladder cancer remains a common and insidious disease. Clinical trials have demonstrated efficacy for new treatments in each disease state, but additional work is needed to advance the effectiveness of care. Real world data help bridge the efficacy versus effectiveness gap. Chemotherapy, biological response modifiers, and complete androgen blockade are all promising avenues of clinical research, but their place in routine treatment and integration with standard management policies remains to be defined.
A 2025 bioinformatic study retrieved the top 30 genes associated with bladder carcinoma from a disease gene network database. Gene ontology analysis revealed significant enrichment of cancer-related biological processes. Pathway analysis identified strong associations with head and neck squamous cell carcinoma, cancer pathways, pleural mesothelioma, endometrial cancer, and bladder cancer pathways. Key genes implicated across multiple pathways included CDKN2A, PTEN, EGFR, PIK3CA, HRAS, FGFR3, and TP53. Metabolite analysis showed significant associations with phosphatidylinositol derivatives, highlighting the importance of the PI3K pathway. Drug interaction analysis revealed potential modulatory effects of sertraline, valproic acid, and hydroxyurea on gene expression patterns in bladder carcinoma. The study notes significant overlap with other cancer types suggests common oncogenic mechanisms.
A 2023 review states that urothelial carcinoma comprises more than 90% of urinary bladder tumours. The review highlights molecular pathways for bladder carcinomas and molecular biomarkers for potential target for treatment. It presents new therapeutic targets and agents that are being developed. The review does not report any clinical outcomes or patient data.
What is still missing is validation of these bioinformatic findings in clinical samples, prospective trial designs that test the identified compounds or targets, and patient stratification based on the genetic profiles described. No survival or response rate data from any drug intervention are provided in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Dialnet (Universidad de la Rioja) · 2001 · 0 citations
La noción de sanción administrativa en la STC 276/2000, de 16 de noviembre de 2000: Una nota discrepante
AbstractBladder cancer remains a common and insidious disease in the United States. There have been several advances in the understanding of the biology of bladder cancer, novel diagnostic tools, improvements in multidisciplinary care pathways, and new therapeutics for advanced disease over the past few decades. Clinical trials have demonstrated efficacy for new treatments in each disease state, but additional work is needed to advance the effectiveness of bladder cancer care. Real world data provide critical information regarding patterns of care, adverse events, and outcomes helping to bridge the efficacy versus effectiveness gap.
AbstractWhat is new in the treatment of the urological cancer? Chemotherapy for bladder cancer, biological response modifiers for renal cell cancer, complete androgen blockade in prostate cancer, new approaches in reconstructive surgery and radiotherapy. These are all promising avenues of clinical research, but their place in the routine treatment of patients and their integration with standard management policies remains to be defined.
Turkish Journal of Surgery · 2025 · 0 citations · open access
Genetic profiling and pathway analysis in bladder carcinoma: Implications for therapeutic targeting
AbstractObjective: Bladder carcinoma represents a significant challenge in oncology due to its heterogeneous molecular nature.This study aimed to identify key genetic factors and molecular pathways involved in bladder carcinoma pathogenesis to facilitate the development of targeted therapies. Material and Methods:The top 30 genes associated with bladder carcinoma were retrieved from the disease gene network database.Comprehensive bioinformatic analysis was performed using various enrichment tools, including gene ontology biological process, cellular component, molecular function analyses, and pathway mapping through WikiPathways and metabolite associations through human metabolome database.Drug interactions were evaluated using DrugMatrix data.Results: Gene ontology analysis revealed significant enrichment of cancer-related biological processes, cellular components, and molecular functions.Pathway analysis identified strong associations with head and neck squamous cell carcinoma, cancer pathways, pleural mesothelioma, endometrial cancer, and bladder cancer pathways.Key genes including CDKN2A, PTEN, EGFR, PIK3CA, HRAS, FGFR3, and TP53 were implicated across multiple pathways.Metabolite analysis showed significant associations with phosphatidylinositol derivatives, highlighting the importance of the PI3K pathway.Drug interaction analysis revealed potential modulatory effects of several compounds including sertraline, valproic acid, and hydroxyurea on gene expression patterns in bladder carcinoma. Conclusion:This study provides comprehensive insights into the molecular underpinnings of bladder carcinoma, highlighting interconnected pathways and potential therapeutic targets.The significant overlap with other cancer types suggests common oncogenic mechanisms that could be exploited for therapeutic intervention.Further validation of these findings in clinical samples may facilitate the development of personalized treatment approaches for bladder carcinoma patients.
A Short Overview on Therapeutic Biomarkers for Muscle Invasive Bladder Carcinoma
AbstractUrothelial carcinoma (UC) is the second most common urologic malignancy after prostatic adenocarcinoma. UC comprises more than 90% of urinary bladder tumours. The intense research involving the different molecular aspects of bladder malignancies offers potential opportunities to improve understanding of bladder cancer biology; helps to identify disease earlier; and improves prediction of outcomes or helps targeted therapy. This review highlights the general concepts of the molecular features: molecular pathways for bladder carcinomas and molecular biomarkers for potential target for treatment of UC of the bladder. This discussion could improve the understating of pathogenesis as well as will provide new therapeutic modules, e.g., targeted therapy. This article is a review of bladder cancer genetics, focusing on molecular changes and their significance in the pathogenesis and progression of muscle invasive UC. Also, the relevant genetic biomarkers and their products, and new therapeutic targets and agents that are being developed are presented here.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
